Syed Hussain, MD
Internal Medicine · North Smithfield, RINPI 1144285081
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 73 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $841 and has fallen 79.0% since, to $176 in 2025.
Across 73 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$208
- Boehringer Ingelheim$164
- Johnson & Johnson$126
- Gilead$118
- Indivior Inc.$96
- Novartis$96
- plus $629 from 16 others
Across 24 payments — averaging $6007.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sun Pharmaceutical Industries Inc.$137K
- Boehringer Ingelheim$7K
What the payments were for
- Food & beverage$1,40998%
- Education$282%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $208 |
| Boehringer Ingelheim | 9 | $164 |
| Johnson & Johnson | 7 | $126 |
| Gilead | 1 | $118 |
| Indivior Inc. | 5 | $96 |
| Novartis | 5 | $96 |
| Medtronic | 1 | $71 |
| Novo Nordisk | 4 | $63 |
| E.r. Squibb & Sons, L.L.C. | 2 | $51 |
| Merck | 4 | $50 |
| Pfizer | 3 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $47 |
| AbbVie | 2 | $45 |
| Viatris Specialty LLC | 2 | $42 |
| Mylan Specialty L.p. | 2 | $42 |
| Collegium Pharmaceutical, Inc. | 2 | $36 |
| GSK | 2 | $33 |
| Lilly USA, LLC | 2 | $29 |
| Braeburn Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veklury$118
How this compares
$1,437 in reported general payments places this provider in the 85th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clemastine Fumarate | 41 | $152,286 |
| TrulicityDulaglutide | 128 | $117,492 |
| EliquisApixaban | 175 | $108,337 |
| Diclofenac Potassium | 44 | $108,232 |
| OzempicSemaglutide | 97 | $92,814 |
| JardianceEmpagliflozin | 95 | $70,395 |
| Metformin Er GastricMetformin Hcl | 55 | $54,656 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 209 | $44,234 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 141 | $43,977 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 143 | $42,307 |
| XareltoRivaroxaban | 42 | $32,087 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $27,546 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 57 | $26,925 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $25,776 |
| JanuviaSitagliptin Phosphate | 27 | $19,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo, Premarin | $47 | $155,500327 claims |
| GSKShingrix, Arexvy, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta | $33 | $154,095483 claims |
| Lilly USA, LLCTrulicity | $29 | $117,492128 claims |
| Novo NordiskOzempic, Wegovy | $63 | $110,602111 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $164 | $97,321152 claims |
| Johnson & JohnsonXarelto | $126 | $32,08742 claims |
| AbbVieLinzess, Restasis, Savella | $45 | $28,98945 claims |
| MerckJanuvia | $50 | $19,08727 claims |
| AstraZenecaBrilinta, Symbicort | $208 | $13,81945 claims |
| Indivior Inc.Suboxone | $96 | $7,89915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in North Smithfield
- Michael HeruNorth Smithfield$5K
- William BeliveauJohnson$951K
- Katarzyna Gilek-SeibertProvidence$131K
- Randall InghamProvidence$100K
- Frank D'alessandroLincoln$93K
- Gregory AllenCranston$38K
- Richard RuggieriProvidence$30K
- Gerry OvideProvidence$29K
- Todd ViccioneEast Greenwich$22K
- Brian McCauleyProvidence$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.